Compare Crocs, Inc. (CROX) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Gilead Sciences, Inc. — how do they compare? Crocs, Inc. trades at $131.61 (market cap $6.31B), while Gilead Sciences, Inc. trades at $135.27 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 26.7× Crocs, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Crocs, Inc. pays none. Which is the better fit depends on your goals.
| CROX | GILD | |
|---|---|---|
Market Cap | $6.31B | $168.35B |
Sector | Consumer Staples | Health |
52-Week High | $141.19 | $155.80 |
52-Week Low | $73.39 | $110.56 |
Enterprise Value | $7.83B | $191.42B |
Dividend Yield | — | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
